DeepSeq.AI Company

DeepSeq.AI is revolutionizing AI-driven drug discovery by combining novel high-throughput wet lab assays with explainable generative AI to design biologics optimized for multiple key functions. Our proprietary platform generates massive-scale protein function data and models protein "grammar," enabling the design of therapeutics optimized for conditional binding, manufacturability, efficacy, and more. Validated by paying customers, including several top global biopharma companies, and protected by a granted patent, DeepSeq.AI's technology is setting new standards in biologics discovery. Our approach has been further endorsed by investments from leading biotech accelerators, such as Merck DSS and UC Berkeley SkyDeck, as well as a prestigious NSF and DARPA grant. Together, we are accelerating the future of biologics development.

Total Funding: 150000
Founded Date: 2019-01-01
Industry: Quantum Chemistry
Last Funding Date: 2026-01-07
Funding Status: private
Headquarters: San Francisco,California,United States,North America
Super Industry: Quantum Science Applications
Funding Total Value: 150000
Founders: Andrew Chang,Bernhard Suter,Bernhard Suter,Carey Chern